[{"orgOrder":0,"company":"Carolinas Pain Institute","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Carolinas Pain Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Carolinas Pain Institute \/ BioDelivery Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Carolinas Pain Institute \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Yale University","sponsor":"National Drug Abuse Treatment CTN | The Emmes Company, LLC | National Institute on Drug Abuse | Alameda Health System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Yale University \/ National Drug Abuse Treatment CTN | The Emmes Company, LLC | National Institute on Drug Abuse | Alameda Health System","highestDevelopmentStatusID":"10","companyTruncated":"Yale University \/ National Drug Abuse Treatment CTN | The Emmes Company, LLC | National Institute on Drug Abuse | Alameda Health System"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure \/ Quotient Sciences"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Braeburn","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Braeburn","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Braeburn"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Prolonged Release","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Hennepin Healthcare Research Institute","sponsor":"National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Hennepin Healthcare Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Hennepin Healthcare Research Institute \/ National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"9","companyTruncated":"Hennepin Healthcare Research Institute \/ National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Buprenorphine","moa":"||Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Purdue Pharma \/ MMCAP Infuse","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ MMCAP Infuse"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"New York State Psychiatric Institute | Columbia University | Harvard Medical School (HMS and HSDM) | McLean Hospital | National Institute on Drug Abuse | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"NYU Langone Health \/ New York State Psychiatric Institute | Columbia University | Harvard Medical School (HMS and HSDM) | McLean Hospital | National Institute on Drug Abuse | The Emmes Company, LLC","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ New York State Psychiatric Institute | Columbia University | Harvard Medical School (HMS and HSDM) | McLean Hospital | National Institute on Drug Abuse | The Emmes Company, LLC"},{"orgOrder":0,"company":"Peking University Sixth Hospital","sponsor":"Ping An-Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Peking University Sixth Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Peking University Sixth Hospital \/ Ping An-Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Peking University Sixth Hospital \/ Ping An-Shionogi"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Emergency Medicine Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Emergency Medicine Foundation","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Emergency Medicine Foundation"},{"orgOrder":0,"company":"MaineHealth","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"MaineHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaineHealth \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"11","companyTruncated":"MaineHealth \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Bicycle Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Bicycle Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicycle Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bicycle Health \/ Inapplicable"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virginia Commonwealth University \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ Indivior"},{"orgOrder":0,"company":"Yih-Ing Hser","sponsor":"National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yih-Ing Hser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yih-Ing Hser \/ National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University","highestDevelopmentStatusID":"10","companyTruncated":"Yih-Ing Hser \/ National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University"},{"orgOrder":0,"company":"Friends Research Institute","sponsor":"National Institute on Drug Abuse | Baltimore City Health Department","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Friends Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Friends Research Institute \/ National Institute on Drug Abuse | Baltimore City Health Department","highestDevelopmentStatusID":"9","companyTruncated":"Friends Research Institute \/ National Institute on Drug Abuse | Baltimore City Health Department"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Vancouver Coastal Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Vancouver Coastal Health","highestDevelopmentStatusID":"8","companyTruncated":"University of British Columbia \/ Vancouver Coastal Health"},{"orgOrder":0,"company":"National Institute of Diabetes and Digestive and Kidney Diseases","sponsor":"Hennepin Health Care | New York University | Massachusetts General Hospital | University of Illinois, Chicago | The University of Pittsburgh School of Medicine | University of Washington | University of New Mexico | Rogosin Institute | Vanderbilt Universi","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"National Institute of Diabetes and Digestive and Kidney Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Hennepin Health Care | New York University | Massachusetts General Hospital | University of Illinois, Chicago | The University of Pittsburgh School of Medicine | University of Washington | University of New Mexico | Rogosin Institute | Vanderbilt Universi","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Hennepin Health Care | New York University | Massachusetts General Hospital | University of Illinois, Chicago | The University of Pittsburgh School of Medicine | University of Washington | University of New Mexico | Rogosin Institute | Vanderbilt Universi"},{"orgOrder":0,"company":"Evon Medics","sponsor":"National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Evon Medics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evon Medics \/ National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman","highestDevelopmentStatusID":"8","companyTruncated":"Evon Medics \/ National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Emplicure"}]

Find Clinical Drug Pipeline Developments & Deals for Buprenorphine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : Emplicure

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          November 29, 2022

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Emplicure

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Quotient

                          02

                          Peking University Sixth Hospital

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Peking University Sixth Hospital

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Ping An-Shionogi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Yale University

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Yale University

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : National Drug Abuse Treatment CTN | The Emmes Company, LLC | National Institute on Drug Abuse | Alameda Health System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 10, 2024

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : National Drug Abuse Treatment CTN | The Emmes Company, LLC | National Institute on Drug Abuse | Alameda Health System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The agreement provides low-cost buprenorphine and naloxone tablets to correctional facilities for opioid use disorder treatment.

                          Product Name : Suboxone-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Buprenorphine,Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : MMCAP Infuse

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 25, 2023

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : National Institute on Drug Abuse

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Yih-Ing Hser

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Yih-Ing Hser

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 05, 2023

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : National Institute on Drug Abuse | National Institutes of Health | The Emmes Company, LLC | University of California, Los Angeles | RAND Corporation | Cornell University | Oregon Health and Science University | University of Illinois, Chicago | University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the partnership, Altruix has been selected as a limited distribution partner for Brixadi (buprenorphine), an opioid medication and an extended-release subcutaneous injection indicated for the treatment of moderate to severe opioid use disorder pati...

                          Product Name : Brixadi

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          August 17, 2023

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Altruix

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Brixadi™ (buprenorphine) injection for SC, will be indicated for the treatment of severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with bupre...

                          Product Name : Brixadi

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 23, 2023

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 30, 2023

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Bicycle Health

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Bicycle Health

                          Country arrow
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 09, 2022

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank